Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm study of MDV3100 (enzalutamide) in hormone-naive prostate cancer
2010-021287-16Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Astellas Pharma. Primary endpoint: PSA response at week 25. Started Oct 2010; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2010-021287-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021287-16.